Skip to main content
. 2017 Apr 14;7(6):1731–1741. doi: 10.1534/g3.117.039909

Figure 3.

Figure 3

Deletion of the tumor suppressor Capicua (CIC) in prostate cancer (A) Genome browser display showing a CNV0 event (red dotted line) on chromosome 19 that spans CIC, PAFAH1B3, PRR19, and TMEM145 in the PC3 prostate cancer cell line. (B) Plot of putative chromosomal loss spanning the four-gene region in LNCaP (left panel) and PC3 (right panel). The x-axis represents the genomic position and the y-axis the number of normalized counts. (C) Loss of the chromosome 19 region encompassing CIC, PAFAH1B3, PRR19, and TMEM145 in the ‘Prostate FHCRC 2016’ cBioPortal data set. Individual tumor samples are shown in columns and genes in rows. (D) CIC copy number alterations in primary and metastatic prostate cancer samples from eight clinical data sets interrogated using cBioPortal. (E) Disease-free survival in primary prostate cancer patients with loss of a single CIC gene copy (n = 13 relapse events) is significantly decreased compared to those without any CIC deletion events. ‘The Prostate (MSKCC 2010)’, ‘Prostate (MSKCC 2014)’, and ‘Prostate (TCGA)’ cBioPortal data sets were interrogated. P-values were calculated by Kaplan–Meier analysis (log-rank test). Time denotes years. CNV0, homozygous deletion; CNV1, heterozygous deletion; WT, wild-type.